Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

EVEvan VietoriszYKYulia Kuznetsova

Discussion

Loading...

Member takes

Overview

Longitudinal study shows MRD testing improves patient outcomes in multiple myeloma, suggesting its vital role in treatment.

Key Points

  • To evaluate the real-world impact of measurable residual disease testing on treatment outcomes in multiple myeloma.
  • Longitudinal, retrospective cohort study using data from Flatiron Health Research Database.
  • Included patients with multiple myeloma who received first-line treatment.
  • Analyzed MRD testing patterns and outcomes using Kaplan-Meier and Cox models.
  • 20% of patients had MRD testing with significant testing in community practices.
  • MRD negativity was associated with longer time to next treatment and overall survival.
  • Higher rates of MRD negativity were found in patients receiving autologous stem cell transplants and certain treatment regimens.

Cite This Study

Vietorisz et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da68https://doi.org/10.1182/blood-2025-2789
View Full Paper
Ask AI
Bookmark
Share